Please assess the completion status of the following clinical trial:

Trial Title: Sustainability of Vitamin D Levels After Repletion With Ergocalciferol In Chronic Kidney Disease Stage 5D

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Activated vitamin D administration~* On chronic hemodialysis for ≥ 6 months~* Use of a synthetic biocompatible dialysis membrane~* 25-hydroxyvitamin D levels \< 30 ng/mL~* Corrected serum calcium \< 10.2 mg/dL~* Serum phosphate \< 7 mg/dL~* Iron replete (Ferritin \> 200 ng/mL and transferrin saturation \> 20%)~Exclusion Criteria:~* Current participation in any other investigational drug trial~* Vitamin D deficiency due to a heredity disorder~* Liver disease or failure~* Current or past treatment with ergocalciferol or cholecalciferol ≥ 2000 IU per day (within the past 6 months)~* Treatment with calcimimetics or bisphosphonates within the last 3 months~* Treatment with anti-epileptics or other medications that can effect vitamin D metabolism~* Malnutrition (serum albumin \< 2.5 mg/dL)~* Pregnancy, positive pregnancy test or breastfeeding~* Malignancy or other significant inflammatory disease~* HIV/AIDS

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ergocalciferol (Type: EXPERIMENTAL): Ergocalciferol 50,000 IU by mouth once weekly for 6 months
- Placebo (Type: PLACEBO_COMPARATOR): Placebo by mouth once weekly for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).